Page 64 - Demo

%u041c%u0435%u0434%u0432%u0435%u0434%u0435%u0432 %u0412.%u042d.64 %u2116 4/2024 %u0421%u043e%u0432%u0440%u0435%u043c%u0435%u043d%u043d%u0430%u044f %u0442%u0435%u0440%u0430 %u043f%u0438%u044f %u043f%u0441%u0438%u0445%u0438%u0447%u0435%u0441%u043a%u0438%u0445 %u0440%u0430 %u0441%u0441%u0442%u0440%u043e%u0439%u0441%u0442%u0432 www.psypharma.ru22. %u041d%u0435%u0437%u043d%u0430%u043d%u043e%u0432 %u041d.%u0413., %u041c%u0430%u0440%u0442%u044b%u043d%u0438%u0445%u0438%u043d %u0418.%u0410., %u041c%u043e%u0441%u043e%u043b%u043e%u0432 %u0421.%u041d. %u0414%u0438%u0430%u0433%u043d%u043e%u0441%u0442%u0438%u043a%u0430 %u0438 %u0442%u0435%u0440%u0430%u043f%u0438%u044f %u0442%u0440%u0435%u0432%u043e%u0436%u043d%u044b%u0445 %u0440%u0430%u0441%u0441%u0442%u0440%u043e%u0439%u0441%u0442%u0432 %u0432 %u0420%u043e%u0441%u0441%u0438%u0439%u0441%u043a%u043e%u0439 %u0424%u0435%u0434%u0435%u0440%u0430%u0446%u0438%u0438: %u0440%u0435%u0437%u0443%u043b%u044c%u0442%u0430%u0442%u044b %u043e%u043f%u0440%u043e%u0441%u0430 %u0432%u0440%u0430%u0447%u0435%u0439-%u043f%u0441%u0438%u0445%u0438%u0430%u0442%u0440%u043e%u0432 // %u0421%u043e%u0432%u0440%u0435%u043c%u0435%u043d%u043d%u0430%u044f %u0442%u0435%u0440%u0430%u043f%u0438%u044f %u043f%u0441%u0438%u0445%u0438%u0447%u0435%u0441%u043a%u0438%u0445 %u0440%u0430%u0441%u0441%u0442%u0440%u043e%u0439%u0441%u0442%u0432. %u2013 2017. %u2013 %u2116 2. %u2013 %u0421. 2%u201313. %u2013 https://doi.org/10.21265/PSYPH.2017.41.643722. Neznanov N.G., Martynihin I.A., Mosolov S.N. Diagnostika i terapija trevozhnyh rasstrojstv v Rossijskoj Federacii: rezul%u2019taty oprosa vrachej-psihiatrov // Sovremennaa Terapia Psihiceskih Rasstrojstv. %u2013 2017. %u2013 %u2116 2. %u2013 S. 2%u201313. %u2013 https://doi.org/10.21265/PSYPH.2017.41.643723. %u0413%u0435%u043d%u0435%u0440%u0430%u043b%u0438%u0437%u043e%u0432%u0430%u043d%u043d%u043e%u0435 %u0442%u0440%u0435%u0432%u043e%u0436%u043d%u043e%u0435 %u0440%u0430%u0441%u0441%u0442%u0440%u043e%u0439%u0441%u0442%u0432%u043e. %u041a%u043b%u0438%u043d%u0438%u0447%u0435%u0441%u043a%u0438%u0435 %u0440%u0435%u043a%u043e%u043c%u0435%u043d%u0434%u0430%u0446%u0438%u0438. %u0412%u0437%u0440%u043e%u0441%u043b%u044b%u0435. %u042d%u043b%u0435%u043a%u0442%u0440%u043e%u043d%u043d%u043e%u0435 %u0438%u0437%u0434%u0430%u043d%u0438%u0435. %u041c%u0438%u043d%u0437%u0434%u0440%u0430%u0432 %u0420%u0424. %u2013 %u041c., 2021. %u2013 101 %u0441. %u2013 URL: https://cr.minzdrav.gov.ru/schema/457_2 (%u0434%u0430%u0442%u0430 %u043e%u0431%u0440%u0430%u0449%u0435%u043d%u0438%u044f 12.07.2024).23. Generalizovannoe trevozhnoe rasstrojstvo. Klinicheskie rekomendacii. Vzroslye. Jelektronnoe izdanie. Minzdrav RF. %u2013 M., 2021. %u2013 101 s. %u2013 URL: https://cr.minzdrav.gov.ru/schema/457_2 (data obrashhenija 12.07.2024).24. %u041a%u043e%u0441%u0442%u044e%u043a%u043e%u0432%u0430 %u0415.%u0413. %u0413%u0435%u043d%u0435%u0440%u0430%u043b%u0438%u0437%u043e%u0432%u0430%u043d%u043d%u043e%u0435 %u0442%u0440%u0435%u0432%u043e%u0436%u043d%u043e%u0435 %u0440%u0430%u0441%u0441%u0442%u0440%u043e%u0439%u0441%u0442%u0432%u043e: %u043e%u0441%u043d%u043e%u0432%u044b %u0434%u0438%u0430%u0433%u043d%u043e%u0441%u0442%u0438%u043a%u0438, %u0442%u0435%u0440%u0430%u043f%u0438%u0438 %u0438 %u0441%u043f%u0435%u0446%u0438%u0444%u0438%u0447%u0435%u0441%u043a%u0438%u0435 %u0434%u043b%u044f %u0420%u043e%u0441%u0441%u0438%u0438 %u043f%u0440%u043e%u0431%u043b%u0435%u043c%u044b // %u0421%u043e%u0432%u0440%u0435%u043c%u0435%u043d%u043d%u0430%u044f %u0442%u0435%u0440%u0430%u043f%u0438%u044f %u043f%u0441%u0438%u0445%u0438%u0447%u0435%u0441%u043a%u0438%u0445 %u0440%u0430%u0441%u0441%u0442%u0440%u043e%u0439%u0441%u0442%u0432. %u2013 2024. %u2013 %u2116 2. %u2013 %u0421. 23%u201331. %u2013 https://doi.org/10.21265/PSYPH.2024.31.31.00324. Kostjukova E.G. Generalizovannoe trevozhnoe rasstrojstvo: osnovy diagnostiki, terapii i specificheskie dlja Rossii problemy // Sovremennaa Terapia Psihiceskih Rasstrojstv. %u2013 2024. %u2013 %u2116 2. %u2013 S. 23%u201331. %u2013 https://doi.org/10.21265/PSYPH.2024.31.31.00325. %u041c%u043e%u0441%u043e%u043b%u043e%u0432 %u0421.%u041d., %u0410%u043b%u0444%u0438%u043c%u043e%u0432 %u041f.%u0412. %u0410%u043b%u0433%u043e%u0440%u0438%u0442%u043c %u0431%u0438%u043e%u043b%u043e%u0433%u0438%u0447%u0435%u0441%u043a%u043e%u0439 %u0442%u0435%u0440%u0430%u043f%u0438%u0438 %u0433%u0435%u043d%u0435%u0440%u0430%u043b%u0438%u0437%u043e%u0432%u0430%u043d%u043d%u043e%u0433%u043e %u0442%u0440%u0435%u0432%u043e%u0436%u043d%u043e%u0433%u043e %u0440%u0430%u0441%u0441%u0442%u0440%u043e%u0439%u0441%u0442%u0432%u0430 // %u0421%u043e%u0432%u0440%u0435%u043c%u0435%u043d%u043d%u0430%u044f %u0442%u0435%u0440%u0430%u043f%u0438%u044f %u043f%u0441%u0438%u0445%u0438%u0447%u0435%u0441%u043a%u0438%u0445 %u0440%u0430%u0441%u0441%u0442%u0440%u043e%u0439%u0441%u0442%u0432. %u2013 2015. %u2013 %u2116 2. %u2013 %u0421. 24%u201328.25. Mosolov S.N., Alfimov P.V. Algoritm biologicheskoj terapii generalizovannogo trevozhnogo rasstrojstva // Sovremennaa Terapia Psihiceskih Rasstrojstv. %u2013 2015. %u2013 %u2116 2. %u2013 S. 24%u201328.26. Gould R.A., Otto M.W., Pollack M.H., Yap L. Cognitive behavioral and pharmacological treatment of generalized anxiety disorder: A preliminary meta-analysis // Behav Ther. %u2013 1997. %u2013 Vol. 28. %u2013 Pp. 285%u2013305. %u2013 https://doi.org/10.1016/s0005- 7894(97)80048-226. Gould R.A., Otto M.W., Pollack M.H., Yap L. Cognitive behavioral and pharmacological treatment of generalized anxiety disorder: A preliminary meta-analysis // Behav Ther. %u2013 1997. %u2013 Vol. 28. %u2013 Pp. 285%u2013305. %u2013 https://doi.org/10.1016/s0005- 7894(97)80048-227. National Institute for Health and Care Excellence. Generalised anxiety disorder and panic disorder in adults: Management. %u2013Available at: https://www. nice.org.uk/guidance/CG113 (accessed January 26, 2011).27. National Institute for Health and Care Excellence. Generalised anxiety disorder and panic disorder in adults: Management. %u2013 Available at: https://www. nice.org.uk/guidance/CG113 (accessed January 26, 2011).28. Slee A., Nazareth I., Bondaronek P., Liu Y., Cheng Z., Freemantle N. Pharmacological treatments for generalised anxiety disorder: A systematic review and network meta-analysis // Lancet. %u2013 2019. %u2013 Vol. 393. %u2013 Pp. 768%u2013777. %u2013https://doi.org/10.1016/s0140- 6736(18)31793-828. Slee A., Nazareth I., Bondaronek P., Liu Y., Cheng Z., Freemantle N. Pharmacological treatments for generalised anxiety disorder: A systematic review and network meta-analysis // Lancet. %u2013 2019. %u2013 Vol. 393. %u2013 Pp. 768%u2013777. %u2013 https://doi.org/10.1016/s0140- 6736(18)31793-829. %u041c%u0435%u0434%u0432%u0435%u0434%u0435%u0432 %u0412.%u042d., %u041a%u043e%u0442%u043e%u0432%u0430 %u041e.%u0412., %u0410%u043a%u0430%u0440%u0430%u0447%u043a%u043e%u0432%u0430 %u0415.%u0421., %u0411%u0435%u043b%u044f%u0435%u0432 %u0410.%u0410., %u041f%u0430%u0440%u0448%u0430%u043a%u043e%u0432%u0430 %u0415.%u0421. %u0413%u0435%u043d%u0435%u0440%u0430%u043b%u0438%u0437%u043e%u0432%u0430%u043d%u043d%u043e%u0435 %u0442%u0440%u0435%u0432%u043e%u0436%u043d%u043e%u0435 %u0440%u0430%u0441%u0441%u0442%u0440%u043e%u0439%u0441%u0442%u0432%u043e: %u0430%u043d%u0430%u0442%u043e%u043c%u0438%u0447%u0435%u0441%u043a%u0438%u0435 %u0438 %u0444%u0443%u043d%u043a%u0446%u0438%u043e%u043d%u0430%u043b%u044c%u043d%u044b%u0435 %u043e%u0441%u043e%u0431%u0435%u043d%u043d%u043e%u0441%u0442%u0438 %u0433%u043e%u043b%u043e%u0432%u043d%u043e%u0433%u043e %u043c%u043e%u0437%u0433%u0430. %u0410%u0432%u0438%u0430%u043d%u0434%u0440 %u2014 %u043d%u043e%u0432%u044b%u0435 %u0432%u043e%u0437%u043c%u043e%u0436%u043d%u043e%u0441%u0442%u0438 %u0442%u0435%u0440%u0430%u043f%u0438%u0438 // %u0421%u043e%u0432%u0440%u0435%u043c%u0435%u043d%u043d%u0430%u044f %u0442%u0435%u0440%u0430%u043f%u0438%u044f %u0432 %u043f%u0441%u0438%u0445%u0438%u0430%u0442%u0440%u0438%u0438 %u0438 %u043d%u0435%u0432%u0440%u043e%u043b%u043e%u0433%u0438%u0438. %u2013 2024. %u2013 %u2116 2. %u2013 %u0421. 14%u201320.29. Medvedev V.Je., Kotova O.V., Akarachkova E.S., Beljaev A.A., Parshakova E.S. Generalizovannoe trevozhnoe rasstrojstvo: anatomicheskie i funkcional%u2019nye osobennosti golovnogo mozga. Aviandr %u2014 novye vozmozhnosti terapii // Sovremennaa Terapia Psihiceskih Rasstrojstv. %u2013 2024. %u2013 %u2116 2. %u2013 S. 14%u201320.30. Buoli M., Caldiroli A., Caletti E. et al. New approaches to the pharmacological management of generalized anxiety disorder // Expert Opin Pharmacother. %u2013 2013. %u2013 Vol. 14 (2). %u2013 Pp. 175%u2013184.30. Buoli M., Caldiroli A., Caletti E. et al. New approaches to the pharmacological management of generalized anxiety disorder // Expert Opin Pharmacother. %u2013 2013. %u2013 Vol. 14 (2). %u2013 Pp. 175%u2013184.31. Pollack M.H. Refractory generalized anxiety disorder // J Clin Psychiatry. %u2013 2009. %u2013 Vol. 70, suppl. 2. %u2013 Pp. 32%u201338.31. Pollack M.H. Refractory generalized anxiety disorder // J Clin Psychiatry. %u2013 2009. %u2013 Vol. 70, suppl. 2. %u2013 Pp. 32%u201338.32. Kapczinski F., Lima M.S., Souza J.S. et al. Antidepressants for generalized anxiety disorder // Cochrane Database Syst Rev. %u2013 2003. %u2013 CD003592.32. Kapczinski F., Lima M.S., Souza J.S. et al. Antidepressants for generalized anxiety disorder // Cochrane Database Syst Rev. %u2013 2003. %u2013 CD003592.33. Montgomery S.A., Kennedy S.H., Burrows G.D. et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: A randomized, double-blind, placebo-controlled discontinuation study // Int Clin Psychopharmacol. %u2013 2004. %u2013 Vol. 19. %u2013 Pp. 271%u2013280.33. Montgomery S.A., Kennedy S.H., Burrows G.D. et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: A randomized, double-blind, placebo-controlled discontinuation study // Int Clin Psychopharmacol. %u2013 2004. %u2013 Vol. 19. %u2013 Pp. 271%u2013280.34. %u0410%u0432%u0435%u0434%u0438%u0441%u043e%u0432%u0430 %u0410.%u0421., %u0417%u0430%u0445%u0430%u0440%u043e%u0432%u0430 %u041a.%u0412., %u041c%u0430%u0440%u0430%u0447%u0435%u0432 %u00a0%u041c.%u041f. %u042d%u0444%u0444%u0435%u043a%u0442%u0438%u0432%u043d%u043e%u0441%u0442%u044c %u043f%u0440%u0435%u043f%u0430%u0440%u0430%u0442%u0430 %u0430%u0433%u043e%u043c%u0435%u043b%u0430%u0442%u0438%u043d (%u0412%u0430%u043b%u044c%u0434%u043e%u043a%u0441%u0430%u043d) %u043f%u0440%u0438 %u043b%u0435%u0447%u0435%u043d%u0438%u0438 %u043f%u0430%u0446%u0438%u0435%u043d%u0442%u043e%u0432 %u0441 %u0442%u0440%u0435%u0432%u043e%u0436%u043d%u043e%u0439 %u0434%u0435%u043f%u0440%u0435%u0441%u0441%u0438%u0435%u0439 %u0432 %u0440%u0430%u043c%u043a%u0430%u0445 %u0431%u043e%u043b%u044c%u0448%u043e%u0433%u043e %u0434%u0435%u043f%u0440%u0435%u0441%u0441%u0438%u0432%u043d%u043e%u0433%u043e %u0440%u0430%u0441%u0441%u0442%u0440%u043e%u0439%u0441%u0442%u0432%u0430. %u0420%u0435%u0437%u0443%u043b%u044c%u0442%u0430%u0442%u044b %u043e%u0431%u0441%u0435%u0440%u0432%u0430%u0446%u0438%u043e%u043d%u043d%u043e%u0439 %u043f%u0440%u043e%u0433%u0440%u0430%u043c%u043c%u044b %u00ab%u0414%u0416%u0410%u0417%u00bb // %u041f%u0441%u0438%u0445%u0438%u0430%u0442%u0440%u0438%u044f %u0438 %u043f%u0441%u0438%u0445%u043e%u0444%u0430%u0440%u043c%u0430%u043a%u043e%u0442%u0435%u0440%u0430%u043f%u0438%u044f %u0438%u043c%u0435%u043d%u0438 %u041f.%u0411. %u0413%u0430%u043d%u043d%u0443%u0448%u043a%u0438%u043d%u0430. %u2013 2013. %u2013 %u2116 6. %u2013 %u0421. 14%u201322.34. Avedisova A.S., Zaharova K.V., Marachev M.P. Jeffektivnost%u2019 preparata agomelatin (Val%u2019doksan) pri lechenii pacientov s trevozhnoj depressiej v ramkah bol%u2019shogo depressivnogo rasstrojstva. Rezul%u2019taty observacionnoj programmy %u00abDZhAZ%u00bb // Psihiatrija i psihofarmakoterapija imeni P.B. Gannushkina. %u2013 2013. %u2013 %u2116 6. %u2013 S. 14%u201322.35. %u041c%u043e%u0441%u043e%u043b%u043e%u0432 %u00a0%u0421.%u041d. %u0425%u0440%u043e%u043d%u043e%u0431%u0438%u043e%u043b%u043e%u0433%u0438%u0447%u0435%u0441%u043a%u0430%u044f %u0442%u0435%u043e%u0440%u0438%u044f %u0430%u0444%u0444%u0435%u043a%u0442%u0438%u0432%u043d%u044b%u0445 %u0440%u0430%u0441%u0441%u0442%u0440%u043e%u0439%u0441%u0442%u0432. %u2013 %u041c.: %u0410%u0412%u0410%u041d%u041f%u041e%u0420%u0422,2014. %u2013 352 %u0441.35. Mosolov S.N. Hronobiologicheskaja teorija affektivnyh rasstrojstv. %u2013 M.: AVANPORT, 2014. %u2013 352 s.36. %u041f%u0435%u0442%u0435%u043b%u0438%u043d %u0414.%u0421., %u041d%u0438%u0439%u043d%u043e%u044f %u0418.%u0412., %u0421%u043e%u0440%u043e%u043a%u0438%u043d%u0430 %u041e.%u0412. %u0438 %u0434%u0440. %u0422%u0435%u0440%u0430%u043f%u0438%u044f %u0441%u043c%u0435%u0448%u0430%u043d%u043d%u043e%u0433%u043e %u0442%u0440%u0435%u0432%u043e%u0436%u043d%u043e%u0433%u043e %u0438 %u0434%u0435%u043f%u0440%u0435%u0441%u0441%u0438%u0432%u043d%u043e%u0433%u043e %u0440%u0430%u0441%u0441%u0442%u0440%u043e%u0439%u0441%u0442%u0432%u0430: %u0440%u0435%u0437%u0443%u043b%u044c%u0442%u0430%u0442%u044b %u043e%u0431%u0441%u0435%u0440%u0432%u0430%u0446%u0438%u043e%u043d%u043d%u043e%u0433%u043e %u0438%u0441%u0441%u043b%u0435%u0434%u043e%u0432%u0430%u043d%u0438%u044f %u044d%u0444%u0444%u0435%u043a%u0442%u0438%u0432%u043d%u043e%u0441%u0442%u0438 %u0438 %u043f%u0435%u0440%u0435%u043d%u043e%u0441%u0438%u043c%u043e%u0441%u0442%u0438 %u0430%u0433%u043e%u043c%u0435%u043b%u0430%u0442%u0438%u043d%u0430 // %u041d%u0435%u0432%u0440%u043e%u043b%u043e%u0433%u0438%u044f, %u043d%u0435%u0439%u0440%u043e%u043f%u0441%u0438%u0445%u0438%u0430%u0442%u0440%u0438%u044f, %u043f%u0441%u0438%u0445%u043e%u0441%u043e%u043c%u0430%u0442%u0438%u043a%u0430. %u2013 2021. %u2013 %u0422. 13 (6). %u2013 %u0421. 48%u201354. %u2013 https://doi.org/10.14412/2074-2711-2021-6-48-5436. Petelin D.S., Nijnoja I.V., Sorokina O.V. i dr. Terapija smeshannogo trevozhnogo i depressivnogo rasstrojstva: rezul%u203ataty observacionnogo issledovanija jeffektivnosti i perenosimosti agomelatina // Nevrologija, nejropsihiatrija, psihosomatika. %u2013 2021. %u2013 T. 13 (6). %u2013 S. 48%u201354. %u2013 https://doi.org/10.14412/2074-2711-2021-6-48-5437. Kennedy S.H., Avedisova A., Gim%u0435%ue088 nez-Montesinos N. et al. A placebo-controlled study of three agomelatine dose regimens (10 mg, 25 mg, 25%u201350 mg) in patients with major depressive disorder // European Neuropsychopharmacology. %u2013 2014. %u2013 %u0422. 24, %u2116 4. %u2013 %u0421. 553%u2013563. 37. Kennedy S.H., Avedisova A., Gim%u0435%ue088 nez-Montesinos N. et al. A placebo-controlled study of three agomelatine dose regimens (10 mg, 25 mg, 25%u201350 mg) in patients with major depressive disorder // European Neuropsychopharmacology. %u2013 2014. %u2013 %u0422. 24, %u2116 4. %u2013 %u0421. 553%u2013563.38. %u0413%u0443%u0448%u0430%u043d%u0441%u043a%u0430%u044f %u0415.%u0412., %u0424%u0440%u043e%u043b%u043e%u0432%u0430 %u0412.%u0418., %u041c%u0435%u0434%u0432%u0435%u0434%u0435%u0432 %u0412.%u042d. %u0422%u0435%u0440%u0430%u043f%u0438%u044f %u0442%u0440%u0435%u0432%u043e%u0436%u043d%u043e%u0439 %u0434%u0435%u043f%u0440%u0435%u0441%u0441%u0438%u0438 (%u043e%u043f%u044b%u0442 %u043f%u0440%u0438%u043c%u0435%u043d%u0435%u043d%u0438%u044f %u0412%u0430%u043b%u044c%u0434%u043e%u043a%u0441%u0430%u043d%u0430) // %u0416%u0443%u0440%u043d%u0430%u043b %u043f%u0441%u0438%u0445%u0438%u0430%u0442%u0440%u0438%u0438 %u0438 %u043f%u0441%u0438%u0445%u043e%u0444%u0430%u0440%u043c%u0430%u043a%u043e%u0442%u0435%u0440%u0430%u043f%u0438%u0438. %u2013 2015. %u2013 %u2116 1. %u2013 %u0421. 17%u201321.38. Gushanskaja E.V., Frolova V.I., Medvedev V.Je. Terapija trevozhnoj depressii (opyt primenenija Val%u2019doksana) // Zhurnal psihiatrii i psihofarmakoterapii. %u2013 2015. %u2013 %u2116 1. %u2013 S. 17%u201321.39. %u041c%u0435%u0434%u0432%u0435%u0434%u0435%u0432 %u0412.%u042d. %u042d%u0444%u0444%u0435%u043a%u0442%u0438%u0432%u043d%u043e%u0441%u0442%u044c %u0438 %u043f%u0435%u0440%u0435%u043d%u043e%u0441%u0438%u043c%u043e%u0441%u0442%u044c %u0441%u043e%u0432%u0440%u0435%u043c%u0435%u043d%u043d%u044b%u0445 %u0430%u043d%u0442%u0438%u0434%u0435%u043f%u0440%u0435%u0441%u0441%u0430%u043d%u0442%u043e%u0432: %u0440%u0435%u0437%u0443%u043b%u044c%u0442%u0430%u0442%u044b %u0441%u0435%u0442%u0435%u0432%u044b%u0445 %u043c%u0435%u0442%u0430%u0430%u043d%u0430%u043b%u0438%u0437%u043e%u0432 %u0438 %u0440%u043e%u0441%u0441%u0438%u0439%u0441%u043a%u0438%u0439 %u043e%u043f%u044b%u0442 // %u0416%u0443%u0440%u043d%u0430%u043b %u043d%u0435%u0432%u0440%u043e%u043b%u043e%u0433%u0438%u0438 %u0438 %u043f%u0441%u0438%u0445%u0438%u0430%u0442%u0440%u0438%u0438 %u0438%u043c%u0435%u043d%u0438 %u0421.%u0421. %u041a%u043e%u0440%u0441%u0430%u043a%u043e%u0432%u0430. %u2013 2018. %u2013 Vol. 118 (11). %u2013 %u0421. 109%u2013117. %u2013 https://doi.org/10.17116/jnevro201811811110939. Medvedev V.Je. Jeffektivnost%u2019 i perenosimost%u2019 sovremennyh antidepressantov: rezul%u2019taty setevyh metaanalizov i rossijskij opyt // Zhurnal nevrologii i psihiatrii imeni S.S. Korsakova. %u2013 2018. %u2013 Vol. 118 (11). %u2013 S. 109%u2013117. %u2013 https://doi.org/10.17116/jnevro201811811110940. %u0427%u0435%u0440%u043d%u043e%u0432%u0430 %u0415.%u0412., %u041a%u043e%u0436%u0435%u0447%u043a%u0438%u043d%u0430 %u041e.%u0412., %u0422%u0435%u0440-%u0418%u0441%u0440%u0430%u0435%u043b%u044f%u043d %u0410.%u042e. %u0438 %u0434%u0440. %u042d%u0444%u0444%u0435%u043a%u0442%u0438%u0432%u043d%u043e%u0441%u0442%u044c %u0438 %u043f%u0435%u0440%u0435%u043d%u043e%u0441%u0438%u043c%u043e%u0441%u0442%u044c %u0430%u0433%u043e%u043c%u0435%u043b%u0430%u0442%u0438%u043d%u0430 (%u0412%u0430%u043b%u044c%u0434%u043e%u043a%u0441%u0430%u043d) %u043f%u0440%u0438 %u0442%u0435%u0440%u0430%u043f%u0438%u0438 %u044d%u043d%u0434%u043e%u0433%u0435%u043d%u043d%u044b%u0445 %u0434%u0435%u043f%u0440%u0435%u0441%u0441%u0438%u0439 %u0432 %u0443%u0441%u043b%u043e%u0432%u0438%u044f %u0434%u043d%u0435%u0432%u043d%u043e%u0433%u043e %u0441%u0442%u0430%u0446%u0438%u043e%u043d%u0430%u0440%u0430 // %u0416%u0443%u0440%u043d%u0430%u043b %u043d%u0435%u0432%u0440%u043e%u043b%u043e%u0433%u0438%u0438 %u0438 %u043f%u0441%u0438%u0445%u0438%u0430%u0442%u0440%u0438%u0438 %u0438%u043c%u0435%u043d%u0438 %u0421.%u0421. %u041a%u043e%u0440%u0441%u0430%u043a%u043e%u0432%u0430. %u2013 2016. %u2013 %u2116 10. %u2013 C. 43%u201346. %u2013 https://doi.org/10.17116/jnevro201611610143-4640. Chernova E.V., Kozhechkina O.V., Ter-Israeljan A.Ju. i dr. Jeffektivnost%u2019 i perenosimost%u2019 agomelatina (Val%u2019doksan) pri terapii jendogennyh depressij v uslovija dnevnogo stacionara // Zhurnal nevrologii i psihiatrii imeni S.S. Korsakova. %u2013 2016. %u2013 %u2116 10. %u2013 C. 43%u201346. %u2013 https://doi.org/10.17116/jnevro201611610143-4641. Kennedy S.H., Avedisova A., Bela%u00efdi C. et al. Sustained efficacy of agomelatine 10 mg, 25 mg, and 25%u201350 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months // European Neuropsychopharmacology. %u2013 2016. %u2013 Vol. 26, no. 2. %u2013 Pp. 378%u2013389. %u2013https://doi.org/10.1016/j.euroneuro.2015.09.006 41. Kennedy S.H., Avedisova A., Bela%u00efdi C. et al. Sustained efficacy of agomelatine 10 mg, 2 mg,and 25%u201350 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months // European Neuropsychopharmacology. %u2013 2016. %u2013 Vol. 26, no. 2. %u2013 Pp. 378%u2013389. %u2013https://doi.org/10.1016/j.euroneuro.2015.09.00642. %u041c%u0435%u0434%u0432%u0435%u0434%u0435%u0432 %u0412.%u042d., %u041a%u043e%u0442%u043e%u0432%u0430 %u041e.%u0412., %u041f%u0430%u043b%u0438%u043d %u0410.%u0412., %u041c%u0438%u0445%u0435%u0435%u0432%u0430 %u041e.%u0412., %u0410%u043a%u0430%u0440%u0430%u0447%u043a%u043e%u0432%u0430 %u0415.%u0421. %u0410%u0433%u043e%u043c%u0435%u043b%u0430%u0442%u0438%u043d: %u0444%u0430%u0440%u043c%u0430%u043a%u043e%u043b%u043e%u0433%u0438%u0447%u0435%u0441%u043a%u0438%u0439 %u043f%u0440%u043e%u0444%u0438%u043b%u044c, %u0432%u043e%u0437%u043c%u043e%u0436%u043d%u043e%u0441%u0442%u0438 %u043f%u0440%u0438%u043c%u0435%u043d%u0435%u043d%u0438%u044f, %u043f%u0440%u0435%u0438%u043c%u0443%u0449%u0435%u0441%u0442%u0432%u0430 // %u041d%u0435%u0432%u0440%u043e%u043b%u043e%u0433%u0438%u044f, %u043d%u0435%u0439%u0440%u043e%u043f%u0441%u0438%u0445%u0438%u0430%u0442%u0440%u0438%u044f, %u043f%u0441%u0438%u0445%u043e%u0441%u043e%u043c%u0430%u0442%u0438%u043a%u0430. %u2013 2024. %u2013 T. 16 (4). %u2013 C. 103%u2013110. %u2013 https://doi.org/10.14412/2074-2711-2024-4-103-11042. Medvedev V.Je., Kotova O.V., Palin A.V., Miheeva O.V., Akarachkova E.S. Agomelatin: farmakologicheskij profil%u2019, vozmozhnosti primenenija, preimushhestva // Nevrologija, nejropsihiatrija, psihosomatika. %u2013 2024. %u2013 T. 16 (4). %u2013 C. 103%u2013110. %u2013 https://doi.org/10.14412/2074-2711-2024-4-103-110